BlossomHill Therapeutics and Latigo Biotherapeutics completed upsized Nasdaq debuts raising a combined $496 million for clinical pipelines, with Latigo specifically securing $345.6 million for non-opioid pain treatments. Conversely, Oxford Biomedica lowered its 2026 revenue guidance to £180M–£200M due to order deferrals, and Novo Nordisk received a downgrade to Sell after reporting weak Q2 earnings. Additionally, health insurers proposed a median 14% premium increase for small businesses to offset rising drug costs.
BlossomHill and Latigo Raise Combined $496M in IPOs
BlossomHill Therapeutics raised $150 million in an upsized initial public offering, selling 9.375 million shares at $16 each on the under the ticker BLSM. The biotech expanded its offering from 7.8 million shares to meet oversubscribed demand. The raise finances a direct challenge to AstraZeneca's standard-of-care lung cancer drug Tagrisso, which brought in more than $7 billion last year. BlossomHill will deploy $70 million to push its lead molecule, BH-30643, through Phase 1/2 trials and into a registrational Phase 2 study. The molecule targets non-small cell lung cancer patients who developed C797S-mediated resistance to third-generation treatments. Competition is fierce. BlossomHill is betting a novel molecular structure can beat established rivals like Tagrisso and Johnson & Johnson’s Rybrevant. The company earmarked another $20 million for an acute myeloid leukemia drug and $5 million to move a pan-KRAS inhibitor into the clinic. Chief Executive Officer Jean Cui previously led Turning Point Therapeutics through a 2019 before Bristol Myers Squibb acquired it for $4.1 billion in 2022. Underwriters can purchase another 1.4 million shares to add $22.5 million to the final proceeds.
Why this matters
Track record in oncology exits allows management teams to oversubscribe public offerings despite challenging a deeply entrenched standard-of-care incumbent with a novel resistance-targeting molecule.
Oxford Biomedica Cuts 2026 Revenue Guidance on Delayed Client Orders
Oxford Biomedica shares fell more than 24% after the company slashed its 2026 forecast to between £180 million and £200 million, down from a previous range of £220 million to £240 million. The UK cell and gene therapy specialist operates as a contract development and manufacturing organization, producing complex biological treatments for third-party biotech and pharmaceutical clients rather than selling its own proprietary drugs. suffered when a major client altered its procurement pathway and pushed back project timelines, alongside broader order deferrals across selected client programs. Integration setbacks worsened the commercial drop. Operational readiness at a newly acquired manufacturing plant in Durham, North Carolina, fell six months behind schedule, delaying client runs and squeezing expected 2026 core margins into the mid-single digits. Gross cash fell from £97 million in December to £75 million by the end of June. The slide marked the stock's worst single-day trading performance since June 2013. Despite the short-term cut, management maintained its long-term target of reaching £500 million in annual by 2030.
Why this matters
For cell and gene CDMOs, revenue visibility is structurally tied to third-party clinical execution, exposing fixed transatlantic manufacturing overhead to sudden client procurement shifts.
Novo Nordisk faces rating downgrade following weak Q2 earnings
Seeking downgraded Novo Nordisk A/S to a Sell rating after falling profits and weak Q2 growth forced the drugmaker to project flat to negative sales growth for 2026. The contrasts sharply with Eli Lilly's robust growth trajectory and expanding pipeline. Semaglutide generated roughly 70% of Novo Nordisk's Q2 revenues, leaving the core business heavily dependent on a single franchise. Patent expiries, manufacturing setbacks, and pipeline disappointments are now eroding the company's first-mover advantage in obesity and diabetes. With no major catalysts on the horizon, the stock faces greater risk over the next six to twelve months than upside.
Why this matters
Relying on a single semaglutide franchise exposes Novo Nordisk to severe valuation compression as manufacturing bottlenecks and pipeline delays stall growth relative to diversified competitors.
Rest of the brief
4 more stories in today’s Healthcare & Pharma, with the figures and the framing that go with them.
